Overview

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

Primary Objective: - To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with type 2 diabetes mellitus Secondary Objectives: - To compare the efficacy of insulin glargine new formulation and Lantus in terms of occurrence of nocturnal Hypoglycemia

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc